AU4010395A - Compositions for increased bioavailability of orally delivered therapeutic agents - Google Patents

Compositions for increased bioavailability of orally delivered therapeutic agents

Info

Publication number
AU4010395A
AU4010395A AU40103/95A AU4010395A AU4010395A AU 4010395 A AU4010395 A AU 4010395A AU 40103/95 A AU40103/95 A AU 40103/95A AU 4010395 A AU4010395 A AU 4010395A AU 4010395 A AU4010395 A AU 4010395A
Authority
AU
Australia
Prior art keywords
compositions
therapeutic agents
increased bioavailability
orally delivered
delivered therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU40103/95A
Inventor
Alan D Habberfield
Kathleen Jensen-Pippo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU4010395A publication Critical patent/AU4010395A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
AU40103/95A 1994-10-27 1995-10-20 Compositions for increased bioavailability of orally delivered therapeutic agents Abandoned AU4010395A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US331393 1981-12-16
US33139394A 1994-10-27 1994-10-27
PCT/US1995/013749 WO1996013250A1 (en) 1994-10-27 1995-10-20 Compositions for increased bioavailability of orally delivered therapeutic agents

Publications (1)

Publication Number Publication Date
AU4010395A true AU4010395A (en) 1996-05-23

Family

ID=23293763

Family Applications (1)

Application Number Title Priority Date Filing Date
AU40103/95A Abandoned AU4010395A (en) 1994-10-27 1995-10-20 Compositions for increased bioavailability of orally delivered therapeutic agents

Country Status (2)

Country Link
AU (1) AU4010395A (en)
WO (1) WO1996013250A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003035A1 (en) * 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Polymerized liposomes with enhanced stability for oral delivery
US6004534A (en) * 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US6060082A (en) * 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
WO1998052604A1 (en) * 1997-05-23 1998-11-26 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Therapeutic or prophylactic use of fibronectin-binding protein i (sfbi) as adjuvant
JP2002507392A (en) * 1998-02-11 2002-03-12 マキシジェン， インコーポレイテッド Optimization of immunomodulatory properties of gene vaccines
AU6235799A (en) * 1998-09-10 2000-04-03 Ignacio Arencibia New use
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ES2300568T3 (en) 2002-03-20 2008-06-16 Mannkind Corporation INHALATION APPARATUS
MX2007001903A (en) 2004-08-20 2007-08-02 Mannkind Corp Catalysis of diketopiperazine synthesis.
KR101306384B1 (en) 2004-08-23 2013-09-09 맨카인드 코포레이션 Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery
AU2014271222B2 (en) * 2005-09-14 2016-04-28 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
JP5465878B2 (en) * 2005-09-14 2014-04-09 マンカインド コーポレイション Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
CN101262849A (en) * 2005-09-14 2008-09-10 曼金德公司 Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
CN104383546B (en) 2006-02-22 2021-03-02 曼金德公司 Method for improving the pharmaceutical properties of microparticles comprising diketopiperazines and an active agent
CN104689432B (en) 2008-06-13 2018-07-06 曼金德公司 Diskus and the system for drug conveying
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
JP5479465B2 (en) 2008-06-20 2014-04-23 マンカインド コーポレイション Interactive device and method for profiling inhalation efforts in real time
TWI494123B (en) 2008-08-11 2015-08-01 Mannkind Corp Use of ultrarapid acting insulin
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
PL2405963T3 (en) 2009-03-11 2014-04-30 Mannkind Corp Apparatus, system and method for measuring resistance of an inhaler
EP2440184B1 (en) 2009-06-12 2023-04-05 MannKind Corporation Diketopiperazine microparticles with defined specific surface areas
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
RU2571331C1 (en) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Systems and methods for dry powder drug delivery
US9387152B2 (en) 2010-06-28 2016-07-12 The General Hospital Corporation Blood substitutes and uses thereof
DK2694402T3 (en) 2011-04-01 2017-07-03 Mannkind Corp BLISTER PACKAGE FOR PHARMACEUTICAL CYLINDER AMPULS
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AU2012328885B2 (en) 2011-10-24 2017-08-31 Mannkind Corporation Methods and compositions for treating pain
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
BR112016000937A8 (en) 2013-07-18 2021-06-22 Mannkind Corp dry powder pharmaceutical formulations, method for making a dry powder formulation and use of a dry powder pharmaceutical formulation
JP2016530930A (en) 2013-08-05 2016-10-06 マンカインド コーポレイション Ventilation device and method
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
WO2016023591A1 (en) * 2014-08-14 2016-02-18 Helmholtz-Zentrum Für Infektionsforschung Methods and compositions of carrier systems for the purpose of intracellular drug targeting
EP3179984A1 (en) * 2014-08-14 2017-06-21 Helmholtz-Zentrum für Infektionsforschung GmbH Methods and compositions of carrier systems for the purpose of intracellular drug targeting
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
CN109996809A (en) 2016-11-14 2019-07-09 诺华股份有限公司 Composition relevant to fusogenic protein MINION, method and therapeutical uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310654A (en) * 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
GB8826116D0 (en) * 1988-11-08 1988-12-14 Danbiosyst Ltd Adhesive drug delivery composition
IE921050A1 (en) * 1991-04-02 1992-10-07 Biotech Australia Pty Ltd Oral delivery systems for microparticles
CA2151742C (en) * 1993-02-22 1999-05-25 Alfred A. Amkraut Compositions for oral delivery of active agents

Also Published As

Publication number Publication date
WO1996013250A1 (en) 1996-05-09

Similar Documents

Publication Publication Date Title
AU4010395A (en) Compositions for increased bioavailability of orally delivered therapeutic agents
AU2053597A (en) Pharmaceutical compositions for the treatment of glaucoma
ZA969001B (en) Method compositions and kits for increasing the oral bioavailability of pharmaceutical agents
AU6011496A (en) Improved pharmaceutical compositions for gene therapy
NZ304982A (en) Pyridinyloxy- or pyridinylamino-acetamide derivatives; pharmaceutical compositions
HUP9900457A3 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
AU6094996A (en) Diphosphonate derivatives of therapeutic agents
AU6517196A (en) Piperazine derivatives as therapeutic agents
AU6216296A (en) Pharmaceutical compositions
AU7256296A (en) Use of metallofluorocomplexes for dental compositions
HU9800291D0 (en) Use of amido-pirimidine derivatives for producing pharmaceutical compositions for inhibiting decrease of glucose-metabolismus
AU2998095A (en) Pharmaceutical compositions comprising vitamin-d analogs
AU1774097A (en) Pharmaceutical compositions for the treatment of rhinitis
HUP0004071A3 (en) Pharmaceutical compositions comprising prostaglandin derivatives
PL339461A1 (en) Orally administered compositions containing levosimendane
AU3107197A (en) Medicinal compositions for treating liver diseases
AU6858996A (en) Pharmaceutical compositions for the treatment of infectious diseases
AU3481795A (en) Pharmaceutical compositions containing d2o
AU1354495A (en) Formulations for orally administered pharmaceutical agents
AU7728698A (en) Oral formulations for treatment of bacteria-induced diseases of the colon
AU5274096A (en) Pharmaceutical compositions
AU1847695A (en) Pharmaceutical formulations of cntf
AU3191597A (en) Novel medicinal compositions of hydropyridines
AU5526196A (en) Compositions for the treatment of dandruff
HUP0003803A3 (en) Use of flunarizine for producing pharmaceutical compositions useful for the topical treating of glaucoma